LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Search

Odonate Therapeutics Inc

Închisă

0

Rezumat

Modificarea prețului

24h

Curent

Minim

Maxim

Indicatori cheie

By Trading Economics

Odonate Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

22 feb. 2026, 23:55 UTC

Market Talk

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22 feb. 2026, 23:53 UTC

Market Talk

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22 feb. 2026, 23:53 UTC

Market Talk

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22 feb. 2026, 23:51 UTC

Market Talk

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22 feb. 2026, 23:35 UTC

Market Talk

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22 feb. 2026, 23:21 UTC

Câștiguri

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22 feb. 2026, 23:20 UTC

Câștiguri

Nickel Industries 2025 Operating Profit US$126.4 Million

22 feb. 2026, 23:19 UTC

Câștiguri

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22 feb. 2026, 23:19 UTC

Câștiguri

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22 feb. 2026, 23:18 UTC

Câștiguri

Nickel Industries Won't Pay a Final Dividend

22 feb. 2026, 23:16 UTC

Câștiguri

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22 feb. 2026, 21:35 UTC

Câștiguri

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22 feb. 2026, 21:34 UTC

Câștiguri

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22 feb. 2026, 21:34 UTC

Câștiguri

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22 feb. 2026, 21:33 UTC

Câștiguri

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22 feb. 2026, 21:33 UTC

Câștiguri

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22 feb. 2026, 21:28 UTC

Câștiguri

Ampol Final Dividend A$0.60/Share

22 feb. 2026, 21:28 UTC

Câștiguri

Ampol FY Revenue A$31.37 Billion, Down 10%

22 feb. 2026, 21:28 UTC

Câștiguri

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22 feb. 2026, 21:28 UTC

Câștiguri

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21 feb. 2026, 14:31 UTC

Achiziții, Fuziuni, Preluări

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21 feb. 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

20 feb. 2026, 23:12 UTC

Achiziții, Fuziuni, Preluări

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20 feb. 2026, 22:12 UTC

Câștiguri

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20 feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20 feb. 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20 feb. 2026, 21:23 UTC

Câștiguri

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20 feb. 2026, 21:20 UTC

Market Talk

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20 feb. 2026, 21:01 UTC

Achiziții, Fuziuni, Preluări

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20 feb. 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Comparație

Modificare preț

Odonate Therapeutics Inc Așteptări

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

EBITDA

Profit operațional

$

Despre Odonate Therapeutics Inc

Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.
help-icon Live chat